Karyopharm Therapeutics reported mixed Phase 3 results for Xpovio (selinexor) in myelofibrosis, with the drug achieving one co-primary endpoint while missing the other. The trial tested Xpovio in combination with Incyte's Jakafi (ruxolitinib) for treating the rare blood disorder that affects bone marrow function.
The study evaluated Xpovio's efficacy on two key measures in myelofibrosis patients, though specific clinical data including patient numbers, response rates, and safety profiles were not detailed in the available reports. Myelofibrosis is a chronic blood cancer that disrupts normal blood cell production in the bone marrow.
The regulatory pathway forward remains unclear given the mixed efficacy results on the co-primary endpoints. Companies typically need to meet both primary endpoints to support FDA approval, though the agency sometimes considers approvals based on single endpoint success depending on clinical benefit and unmet medical need.
Analysts had previously estimated that myelofibrosis could potentially triple Karyopharm's revenue if Xpovio gained approval in the indication. The mixed results may dampen investor enthusiasm and limit the commercial opportunity compared to earlier projections. Karyopharm's stock performance following the data release was not reported.
For myelofibrosis patients, treatment options remain limited beyond existing JAK inhibitors like Jakafi. The mixed trial results suggest Xpovio may provide some clinical benefit, but the failure to meet both primary endpoints could limit its potential impact on patient care.